Cognitive effects of olanzapine treatment in schizophrenia

MedGenMed Medscape General Medicine

Volumn 6, Issue 2, 2004, Pages

  McGurk, Susan R ^a   Lee, M A ^b   Jayathilake, K ^b   Meltzer, Herbert Y ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE; CHLORPROMAZINE; FLUPHENAZINE; HALOPERIDOL; LORAZEPAM; LOXAPINE SUCCINATE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; SERTRALINE; VALPROIC ACID; BENZODIAZEPINE DERIVATIVE;

ADULT; ARTICLE; ATTENTION; CLINICAL ARTICLE; CLINICAL PROTOCOL; COGNITION; FEMALE; HUMAN; LEARNING; MALE; MENTAL DISEASE; MOTOR PERFORMANCE; NEUROLOGIC EXAMINATION; RATING SCALE; SCHIZOPHRENIA; SCORING SYSTEM; TREATMENT OUTCOME; VISION; WORKING MEMORY; DRUG EFFECT;

ADULT; BENZODIAZEPINES; COGNITION; FEMALE; HUMANS; MALE; SCHIZOPHRENIA;

EID: 23444434744     PISSN: None     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. Palmer BW, Heaton RK, Paulsen JS, et al. Is it possible to be schizophrenic yet neuropsychologically normal? Neuropsychology. 1997;11:437-446.
2. Saykin AJ, Shtasel DL, Gur RE, et al. Neuropsychological deficits in neuroleptic naýve patients with first-episode schizophrenia. Arch Gen Psychiatry. 1994;51:124-131.
3. Cornblatt BA, Erlenmeyer-Kimling L. Global attentional deviance as a marker of risk for schizophrenia: specificity and predictive validity. J Abnorm Psychol. 1985;9:470-486.
4. Neuchterlein KH, Dawson ME, Ventura J, Miklowitz D, Konishi G. Information-processing anomalies in the early course of schizophrenia and bipolar disorder. Schizophr Res. 1991;5:195-196.
5. Byrne M, Hodges A, Grant E, Owens DC, Johnstone EC. Neuropsychological assessment of young people at high genetic risk for developing schizophrenia compared with controls: preliminary findings of the Edinbugh High Risk Study (EHRS). Psychol Med. 1999;29:1161-1175.
6. Bilder RM, Goldman RS, Robinson D, et al. Neuropsychology of first episode of schizophrenia: initial characterization and clinical correlates. Am J Psychiatry. 2000;157:549-559.
7. Friedman JI, Harvey PD, Kemether E, Byne W, Davis KL. Cognitive and functional changes with aging in schizophrenia. Biol Psychiatry. 1999;46:921-928.
8. Hoff AL, Sakuma M, Wieneke M, Horon R, Kushner M, DeLisi LE. Longitudinal neuropsychological follow-up study of patients with first episode schizophrenia. Am J Psychiatry. 1999;156:1336-1341.
9. Gold JM, Harvey PD. Cognitive deficits in schizophrenia. Psychiatr Clin North Am. 1993;16:295-312.
10. Kenny JT, Meltzer HY. Attention and higher cortical functions in schizophrenia. J Neuropsychiatry Clin Neurosci. 1991;3:269-275.
11. Braff DL, Heaton R, Kuck J, et al. The generalized pattern of neuropsychological deficits in outpatients with chronic schizophrenia with heterogeneous Wisconsin Card Sorting Test results. Arch Gen Psychiatry. 1991;48:891-898.
12. Tune LE, Strauss ME, Lew MF, Breitlinger E, Coyle JT. Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients. Am J Psychiatry. 1982;139:1460-1462.
13. McEvoy JP, McCue M, Spring B, Mohs RC, Lavori PW, Farr R. The effects of amantadine vs. trihexyphenidyl on memory in elderly normal volunteers. Psychopharmacol Bull. 1987;23:30-32.
14. McEvoy JP, Freter S. The dose-response relationship for memory impairment by anticholinergic drugs. Compr Psychiatry. 1989;30:135-138.
15. Spohn HE, Strauss ME. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol. 1989;98:367-380.
16. Carpenter WT, Gold JM. Letter. Biol Psychiatry. 2003;53:267-268.
17. Calev A, Berlin H, Lerer B. Remote and recent memory in long-hospitalized chronic schizophrenics. Biol Psychiatry. 1987;22:79-85.
18. Mori K, Yamashita H, Nagao M, Horiguchi J, Yamawaki S. Effects of anticholinergic drug withdrawal on memory, regional cerebral blood flow and extrapyramidal side effects in schizophrenic patients. Pharmacopsychiatry. 2002;35:6-11.
19. Bymaster FP, Hemrick-Luecke SK, Perry FW, Fuller FW. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology. 1996;124:87-94.
20. Bymaster FP, Nelson DL, DeLapp NW, et al. Antagonism by olanzapine of dopamine D1, serotonin 2, muscarinic, histamine H1, and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999;37:107-122.
21. Chengappa KN, Pollock BG, Parepally H, et al. Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine. J Clin Psychopharmacol. 2000;20:311-316.
22. Raedler TJ, Knable MB, Jones DW, et al. In vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia. Neuropsychopharmacology. 2000;23:56-68.
23. Lavalaye J, Booij J, Linszen DH, Reneman L, van Royen EA. Higher occupancy of muscarinic receptors by olanzapine than risperidone in patients with schizophrenia. A[123I]-IDEX SPECT study. Psychopharmacology (Berl). 2001;156:53-57.
24. Kennedy JS, Bymaster FP, Schuh L, et al. A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data. Int J Geriatr Psychiatry. 2001;16(suppl 1):S33-S61.
25. Zhang W, Bymaster FP. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors. Psychopharmacology (Berl). 1999;141:267-278.
26. Ichikawa J, Li Z, Dai J, Meltzer HY. Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT(1A) receptor agonism. Brain Res. 2002;956:349-357.
27. Shirazi-Southall S, Rodriguez DE, Nomikos GG. Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology. 2002;26:583-594.
28. Meltzer HY, McGurk SR. The effects of clozapine, risperidone and olanzapine on cognitive functioning in schizophrenia. Schizophr Bull. 1999;25:233-255.
29. Keefe RS, Silva SC, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia. Schizophr Bull. 1999;25:201-222.
30. Cuesta MJ, Peralta V, Zarauela A. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophr Res. 2001;48:17-28.
31. Harvey PD, Keefe RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry. 2001;158:176-184.
32. Cassens G, Inglis AK, Appelbaum PS, Guthell TG. Neuropsychological function in chronic schizophrenic patients. Schizophr Bull. 1990;16:477-499.
33. Lee MA, Jayathilake K, Meltzer HY. A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia. Schizophr Res. 1999;37:1-12.
34. Green MF, Marder SR, Glynn SM, et al. The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiatry. 2002;51:972-978.
35. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153:321-330.
36. McGurk SR, Meltzer HY. The role of cognition in vocational functioning in schizophrenia. Schizophr Res. 2000;45:175-184.
37. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull. 2000;26:119-136.
38. Purdon SE, Jones BD, Stip E, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry. 2000;57:249-258.
39. Smith RC, Infante M, Singh A, Khandat A. The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia. Int J Neuropsychopharmacol. 2001;4:239-250.
40. Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Pyschiatry. 2002;159:6.
41. Bellack AS, Gold JM, Buchanan RW. Cognitive rehabilitation for schizophrenia: problems, prospects, and strategies. Schizophr Bull. 1999;25:257-274.
42. Kane J, Honigfeld G, Singer J, Meltzer HY, Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1989;45:789-796.
43. Berg EA. A simple objective test for measuring flexibility in thinking. J Gen Psychol. 1968;39:15-22.
44. Reitan RM. Manual for administration of neuropsychological test batteries for adults and children. Indianapolis, Ind: Reitan Neuropsychology Laboratories Inc; 1979.
45. Peterson LR, Peterson MJ. Short-term retention of individual verbal items. J Exp Psychol. 1959;58:193-198.
46. McGurk SR, Green MF, Wirshing WC, et al. Antipsychotic and anticholinergic effects on two types of spatial memory in schizophrenia. Schizophr Res. 2004;68:225-233.
47. Benton AL, Hamsher KD. Multilingual Aphasia Examination. Iowa City, Iowa: AJA Associates; 1989.
48. Wechsler D. WAIS-R Manual. Wechsler Adult Intelligence Scale-Revised. New York, NY: Psychological Corp; 1981.
49. Cornblatt B, Risch NJ, Faris G, Friedman D, Erlenmeyer-Kimling L. The Continuous Performance Test, Identical Paris Version (CPT-IP): I. New findings about sustained attention in normal families. Psychiatry Res. 1988;26:223-238.
50. Wechsler D. The Wechsler Intelligence Scale for Children, 3rd ed. San Antonio, Tex: Psychological Corp; 1991.
51. Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning and Memory Test (Manual). San Antonio, Tex: Psychological Corp; 1987.
52. Wechsler D. Wechsler Memory Scale-Revised manual. San Antonio, Tex: Psychological Corp; 1974.
53. Halstead WC. Brain and Intelligence. Chicago, Ill: University of Chicago Press; 1947.
54. Hagger C, Buckley P, Kenny JT, Freidman L, Ubogy D, Meltzer HY. Improvement in cognitive function and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry. 1993;34:702-712.
55. Lee MA, Thompson P, Meltzer HY. Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry. 1994;55(suppl B):8-14.
56. Williams GV, Goldman-Rakic PS. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature. 1995;376:572-575.
57. Bymaster FP, Felder C, Ahmed S, McKinzie D. Muscarinic receptors as a target for drugs treating schizophrenia. Curr Drug Target CNS Neurol Disord. 2002;1:147-164.
58. Hoff AL, Riordan H, O'Donnell DW, Morris L, DeLisi LE. Neuropsychological functioning of first-episode schizophreniform patients. Am J Psychiatry. 1992;149:898-903.
59. Stephan KE, Magnotta VA, White T, et al. Effects of olanzapine on cerebellar functional connectivity in schizophrenia measured by fMRI during a simple motor task. Psychol Med. 2001;31:1065-1078.
60. Braver TS, Barch DM, Cohen JD. Cognition and control in schizophrenia: a computational model of dopamine and prefrontal function. Biol Psychiatry. 1999;46:312-328.
61. Carter CS, Mintun M, Nichols T, Cohen JD. Anterior cingulate gyrus dysfunction and selective attention deficits in schizophrenia: [15O] H2O PET study during single-trial Stroop task performance. Am J Psychiatry. 1997;154:1670-1675.
62. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem. 2001;76:1521-1531.
63. Dawe GS, Huff KD, Vandergriff JL, et al. Olanzapine activates the rat locus coeruleus: in vivo electrophysiology and c-fost immunoreactivity. Biol Psychiatry. 2001;50:510-520.
64. Goldman RS, Axelrod BN, Tandon R, Ribeiro SC, Craig K, Berent S. Neuropsychological prediction of treatment efficacy and one-year outcome in schizophrenia. Psychopathology. 1993;26:122-126.
65. Harey PD, Moriarty PJ, Serper MR, Schnur E, Lieber D. Practice-related improvement in information processing with novel antipsychotic treatment. Schizophr Res. 2000;46:139-148.
66. Gren MF, Marshall BD Jr, Wirshing WC, et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry. 1997;154:799-804.
67. Goldberg TE, Greenberg RD, Griffin SJ, et al. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry. 1993;162:43-48.
68. Kern RS, Green MF, Marshall BD Jr, et al. Risperidone versus haloperidol on secondary memory: can newer medications aid learning? Schizophr Bull. 1999;25:223-232.
69. Hoff AL, Faustman WO, Wieneke M, et al. The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. Neuropsychopharmacology. 1996;15:361-369.
70. Grace J, Bellus SP, Raulin ML, et al. Long-term impact of clozapine and psychosocial treatment of psychiatric symptoms and cognitive functioning. Psychiatr Serv. 1996;4:41-45.
71. Galletly CA, Clark CR, McFarlane AC, Weber DL. Relationships between changes in symptoms ratings, neuropsychological test performance and quality of life in schizophrenic patients with clozapine. Psychiatr Res. 1997;72:161-166.
72. Buchanan RW, Holstein C, Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry. 1994;36:717-725.